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Background: Post treatment lung screening for head and neck cancer patients primarily focuses on the distant
metastasis and a high rate of second primary can also be expected. The best screening tool and timing for this
purpose is controversial. We sought out to assess the current practice and beliefs among Canadian Head and
Neck Surgeons.
Methods: After Ethical Board approval, a nationwide survey was conducted through the Canadian Society of
Otolaryngology (CSO) among head and neck surgeons regarding their practices for pulmonary screening in
HNSCC patients.
Results: Our CSO survey among Otolaryngology-head and neck surgeons showed that 26 out of 32 respondents
perform routine lung screen, out of which 23 (88%) feel that chest radiography should be preferred. The majority of
respondents felt that lung screening could impact beneficially on mortality. For symptomatic patients, low-dose spiral CT
was the preferred modality (48%), followed by PET/CT scan (14%) and sputum cytology (14%). In high-risk asymptomatic
patients (current smoker, radiation exposure, family history and advanced HNSCC), 31% of respondents performed a CXR.
The same percentage performed a low dose CT, while 19% relied on PET scan. A further 19% of respondents did not
perform any screening in high-risk patients. Most respondents (77%) had more than 10 years practice since graduation
from medical school and came from the provinces of Quebec, Ontario and Alberta.
Conclusion: Chest radiography remains the preferred modality for lung screening and was believed to be impacting
beneficially on lung mortality. The recent literature does not seem to be in agreement with those beliefs. Further studies
to establish which modality is best and concurrent nation-wide education are warranted.
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In head and neck squamous cell carcinoma patients
(HNSCC), post treatment surveillance for distant disease
is mostly focusing on the lungs, as HNSCC distant
metastasis occurs in this organ in 90% of the cases and a
high rate of primary of the lungs can be expected due to
field cancerization of the entire upper aerodigestive tract* Correspondence: maddyy@gmail.com
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unless otherwise stated.[1-4]. Furthermore distant metastasis isolated to other
sites such as liver or bones are rare in the absence of
simultaneous pulmonary malignancy [4]. The traditional
method for lung screening has been chest radiography,
as it is widely available, cheap and has a low radiation
dose, which allows for safe repetitive screening [5,6].
Screening for distant metastasis and/or second primary
of the lungs is useful as it allows for prognostication and
adapted patient counselling [7] and in case of early detec-
tion may impact beneficially the prognosis of patients [8].
Early stage lung primary can be treated with curativel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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metastasectomy in selected patients [8]. Overall, screening
for distant metastasis has gained importance in the last
few years, as aggressive locoregional treatment in HNSCC
has led to better locoregional control but higher risk of
distant failure [10]. This reverse failure pattern was first
reported by Vikram et al. [10], who showed that only 15%
of patients relapsed above the clavicle, as opposed to 70%
in historical series.
Chest radiography is, however, likely to be out-dated,
as previously shown by several groups [5,11]. Newer
technologies now widely available such as computer
tomography and positron emission tomography (PET/CT)Table 1 Structure of original questionnaire for nation-wide su
Questions Possible
1. How do you perform routine lung screening during
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3. How effective do you believe the screening procedures
listed in question 1 are in reducing lung cancer mortality





4. Have any of your patients during the past 12 months
inquired about lung screening
Yes
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5. Number of years of your clinical head and neck





6. What is your practicing census region and the patient













Yukonare currently being evaluated as screening tools in
HNSCC [4,5,12-14].
The objective of this study was to evaluate the current
beliefs and practice among Head and Neck surgeon
members of the Canadian Society of Otolaryngology
using a nation-wide survey. The results of this survey
were compared to latest data from the literature in the
discussion.
Methods
After Ethics Review Board approval, a nationwide survey
was conducted through the Canadian Society of Oto-
laryngology (CSO) among Otolaryngology-head and neckrvey
responses
ography All patients
CT Only symptomatic patients
Only high risk patients (smokers, radiation




















t Territories >125 patients/week
Table 2 Wilson and Jungner screening criteria
1. The condition sought should be an important health problem.
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pulmonary screening in HNSCC. A simple survey with
6 questions regarding actual practice was designed pre-
viously, reviewed, and sent to head and neck surgeons
across Canada. A sample of the survey is available in
Table 1.
Results
Our CSO survey among Otolaryngologist - Head and
Neck surgeons showed that 26 out 32 (81%) respondents
perform routine lung screening, out of which 23 (88%)
feel that chest radiography should be preferred versus
low dose CT scan or PET scan for annual pulmonary
screening among all asymptomatic HNSCC patients
during follow up (Figure 1). In asymptomatic patients,
only 2 respondents did not perform any lung screening.
The response rate of the survey was 84.2% (32 out of 38)
and the survey was sent only once.
For symptomatic patients, low-dose spiral CT was the
preferred modality (48%), followed by PET/CT scan (14%)
and sputum cytology (14%).
In high-risk asymptomatic patients (current smoker,
radiation exposure, family history and advanced HNSCC),
31% of respondents performed a CXR. The same percent-
age performed a low dose CT, while 19% relied on PET
scan. A further 19% of respondents did not perform any
screening in high-risk patients.
Seventeen of 28 respondents (60%) request lung
screening for 5 years, while 4 (15%) and 7 (25%) do it
for 10 years and life long, respectively. Most respondents
were screening their patients annually (74%), while less
than 15% did it biennially or half-yearly, respectively.
CXR was believed to be in 11% “very effective” and
50% “somewhat effective” in reducing lung malignancy
mortality during HNSCC follow-up for non-smoker. In
former smokers, the believed efficacy was 14% and 57%,
respectively. In current smoker, CXR was believed to be
“very effective” and “somewhat effective” in 27% and 54%,











Chest radiography Low-dose CT PET/CT
Figure 1 Preferred modality in asymptomatic patients among
COS head and neck surgeons.recall having any patient inquiring about lung screening
in the past 12 months. Most respondents (77%) had more
than 10 years practice since graduation from medical
school and came from the provinces of Quebec, Ontario
and Alberta (11, 10, and 6, respectively).
Discussion
The main goal of this study was to assess the practice
among head and neck surgeons in Canada for post treat-
ment screening. Briefly, we showed that the preferred
modality was chest radiography, done yearly in all patients
for 5 years and this was believed in the majority of cases
to be effective. Let us discuss each part of this statement
point by point, in light of the classic Wilson and Jungner
screening criteria (Table 2) [15].
Target group
As screening is less efficacious if the expected prevalence
is low according to the Bayes theorem, screening has to
target particular groups in order to be cost effective and
avoid high rate of false positive [16]. Previous studies
have shown that patients with advanced tumor stage,
tumor from the hypopharynx and smokers are at higher
risk for pulmonary malignancy [1,17-19]. In human pap-
illoma virus patients, the rate of pulmonary malignancy
may be lower due to lack of field carcinogenesis and a
somewhat different distant metastatic pattern [20,21],
thus requiring different strategies not only in treatment
but also in surveillance.
Screening accuracy and impact on mortality
Although chest radiography remains the preferred and
most widely used screening modality, numerous studies
showed that regular chest radiography was not efficacious
at detecting pulmonary malignancy [5,6,11]. More sensi-
tive methods are required. Computer chest tomography2. There should be an accepted treatment for patients with
recognized disease.
3. Facilities for diagnosis and treatment should be available
4. There should be a recognizable latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from
latent to declared disease, should be adequately understood.
8. There should be an agreed policy on whom to treat as patients.
9. The cost of case finding (including diagnosis and treatment
of patients diagnosed) should be economically balanced in
relation to possible expenditure on medical care as a whole.
10. Case finding should be a continuing process and not a
“once and for all” project.
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whole body MRI (WBMRI) are actually being evaluated
[4,5,12,13,22,23]. CT is now widely available, has a reported
sensitivity and specificity of 73% and 86%, respectively
[22] and recent development such as low dose CT may
compensate for the relative high radiation dose of each
examination, a factor particularly important for repeti-
tive imaging such as in yearly screening [24]. For lung
cancer, it was shown that LDCT could reduce mortality
in some high-risk group such as smokers when LDCT
was used as a screening tool [25]. A recent Cochrane
systematic review came to the conclusion that LDCT
could be beneficial in a high-risk lung cancer group,
but not chest radiography or sputum cytology [26]. In
HNSCC, to our knowledge, no trials are available yet.
PET/CT is deemed to detect more metastasis and
earlier in their course [12,13]. This advantage however
could not be translated into clinical benefit for the
patients in any studies [4,13]. It must be noted that
most of the studies were retrospective and that the
diagnosis of distant metastasis mostly did not change
the treatment, as classically only symptomatic patients
will receive palliative chemotherapy but no specific
intervention was performed in early diagnosis patients
[27]. Classically patients with distant metastasis are
treated only when symptomatic, leading some authors
to argue that screening may have low clinical impact,
and is unlikely to change treatment course [27]. This
may be true for distant metastasis, however second
lung primary may be potentially treated with curative
intent and thus remains important. Furthermore, when
interpreting the literature, one should be cautious not
to interpret the prolonged time between diagnosis and
death as survival advantage, as this may be explained by
lead-time bias [6].
Although PET/CT screens the whole body and this
may seem like a critical advantage, a recent study by
Spector et al. [4] showed that the most common site for
asymptomatic metastasis were the lungs, whereas patients
who developed bone, liver or brain metastasis were typic-
ally identified by imaging initiated by symptoms. This
would suggest that screening (per definition in asymptom-
atic patients) may be sufficient if performed in the lungs
only, as metastasis to other organs are likely to become
rapidly symptomatic and not “detectable” in early disease
course [4]. However, in the province of Ontario, PET/CT
is not approved for routine pulmonary screening and
therefore would not be an option for any surgeon
responding from Ontario. PET/CT scan was believed to
be useful for screening by 19% of respondents (2 from
Quebec; and one from Saskatchewan, Alberta, British
Columbia and New Brunswick each). Baring the Ontario
respondents (10 in number, 31% of total), 27% (6/22) of
the respondents from provinces other than Ontario thinkPET/CT scan is a viable screening tool in high risk head
and neck cancer patients on follow up. Finally newer
studies have shown that WBMRI can be used as screening
tool for HNSCC patients. WBMRI was shown in a pilot
study to be accurate and not to require very long
imaging times [23]. Further studies on that modality
are required.
For sputum cytology, the scarce evidence available on
that matter failed to support any potential use in HNSCC
patients or any lung cancer case [26,28].
Timing and frequency of screening
To our knowledge, the adequate timing and frequency of
screening for lung metastasis is based on empirical evi-
dence. Most head and neck surgeons in Canada preferred
yearly screening for 5 years. As distant metastasis most
commonly occurs within 2 years after the diagnosis [29],
one could wonder if half yearly screening in the first
2 years followed by yearly screening afterwards would
be more adequate [30]. Again, although this may detect
distant disease earlier in the course, it remains to be
proven that this impacts survival beneficially and does
not have negative impact on the health care system [31].
For screening tools with poor sensitivity such as chest
radiography, a recent study showed it was ineffective when
performed twice yearly [31].
Conclusion
Chest radiography remains the preferred screening modal-
ity for distant metastatic HNSCC in Canada, despite lack-
ing sensitivity. Hence the lung screening practices of
head and neck surgeons in Canada are contrary to what
the evidence would suggest, and cannot be justified.
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